“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced ...
Polyrizon Ltd., a pharmaceutical company specializing in preparations, has announced it will hold its Annual General Meeting (AGM) of Shareholders on Thursday, April 17, 2025. The meeting is ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage with a market capitalization of $2.95 million, is progressing in its preclinical studies for an intranasal ...
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Polyrizon's filing of its Annual Report on Form 20-F with the SEC reflects compliance with regulatory requirements, which can enhance the company's credibility and transparency to investors.
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results